223674 BMI Change in a Randomized, Double-blind, Placebo-Controlled Trial of 2 Dosages of Sustained-Release Bupropion for Adolescent Smoking Cessation

Monday, November 8, 2010

Lysbeth Floden, MPH , Family and Community Medicine, University of Arizona, Tucson, AZ
Douglas Taren, PhD , Associate Dean for Academic Affairs and Professor, University of Arizona, Mel & Enid Zuckerman College of Public Health, Tucson, AZ
Scott Leischow, PhD , University of Arizona, Baltimore, AZ
Myra Muramoto, MD, MPH , Family and Community Medicine, University of Arizona, Tucson, AZ
Background: Weight gain after quitting smoking is a barrier to cessation, particularly in younger smokers. A randomized, double-blind, placebo-controlled, dose-ranging trial of sustained-release bupropion in adolescents, ages 14-17 (N = 312) demonstrated that 300 mg/d, plus brief counseling had short-term efficacy for smoking cessation. Initial investigation for this study suggested a change in body mass index (BMI) among study participants and this change may be related to the bupropion dose. The objective of this post-hoc analysis is to determine if there is a statistically significant change in BMI among participants and if this varies by dose. Method: This analysis will use data from weekly participant assessments over a 6 week period during study intervention. Other potential predictors, including final quit smoking status, gender, race, prior dependence addiction, and reported concern for weight gain were also investigated. Results: Marginal analysis identified treatment group, gender and concern for weight change as potential predictors to be included in a regression model. Multivariate linear regression results demonstrated that while controlling for final quit status and treatment group, concern for weight gain (p=0.025) and being female (p=0.039) were positively associated with change in BMI at week 6 of the intervention. A linear mixed model, taking into account the random-effects of participant and weekly visit, indicated significant differences in treatment groups. Specifically, positive change in BMI is inversely related to taking 300mg/d of buprorion versus placebo for smoking cessation (p<0.000). Conclusion: Adolescents taking 300mg/d bupropion for smoking cessation demonstrated changes in BMI.

Learning Areas:
Basic medical science applied in public health

Learning Objectives:
Explain the relationship between bupropion dose and BMI change in adolescents who are quitting smoking Describe other factors related to changes in BMI in adolescents who are taking bupropion for smoking cessation

Keywords: Adolescent Health, Tobacco

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am qualified because I completed all analysis for this paper.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.